Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIL204-SL plus standard chemotherapy versus standard chemotherapy alone for unresectable locally advanced pancreatic cancer with KRAS mutation
MOH_2026-04-16_015772Phase 2Not yet recruiting
- Sponsor
- Silexion Therapeutics
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SIL204-SL in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Silexion Therapeutics. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SIL204-SL
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2026-04-16_015772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-16_015772.